The study to evaluate the effect of supplements on endurance performance

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effect of nicotinamide mononucleotide (NMN) and/or paprika xanthophyll (PX) on endurance performance - The study to evaluate the effect of nicotinamide mononucleotide (NMN) and/or paprika xanthophyll (PX) on endurance performance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049372

Enrollment

240

Registered

2024-12-31

Start date

2022-10-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

Subjects receive 500 mg/day of NMN and 9 mg/day of PX for 8 weeks Subjects receive 500 mg/day of NMN and placebo of PX for 8 weeks Subjects receive 9 mg/day of PX and placebo of NMN for 8 weeks Subjec

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Subjects who agree to the study 2) Healthy adult males between the ages of 18 and 40

Exclusion criteria

Exclusion criteria: 1) Subjects who are unable to refrain from taking health foods, including dietary supplements, and quasi-drugs, over-the-counter drugs during the study. However, subjects who are prescribed pharmaceuticals or other drugs by a physician or pharmacist for therapeutic purposes should ask them for a decision to discontinue. If use is unavoidable, it must be done with the agreement of the research institution. 2) Subjects who habitually consume NMN-containing or PX-containing products. 3) Subjects who are unable to abstain from smoking during the study. 4) Subjects whose BMI are 30.0 kg/m^2 or more. 5) Subjects who have under treatment or a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease) and disease to affect the adrenal cortical hormone secretion. 6) Subjects having a disease requiring treatment or a history of serious diseases for which medication was required. 7) Subjects who may develop allergic symptoms to research foods, or who may develop serious allergic symptoms to other foods or medicines. 8) Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies. 9) Subjects who may change their lifestyle during the study (e.g., long-term travel). 10) Subjects who are judged as unsuitable for the study by their family physician.

Design outcomes

Primary

Measure	Time frame
To evaluate endurance performance by lactate curve test and heart rate	—

Secondary

Measure	Time frame
1) To evaluate NAD+ in blood 2) To evaluate the metabolites in urine and saliva 3) To evaluate body composition	—

Countries

Japan

Contacts

Public ContactHironaga Ito

EUPHORIA Co., Ltd. SPORTS DATA MANAGEMENT DIV.

rinsho_glico@eu-phoria.jp+81-50-1742-8657

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026